ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	112.67	74.29	150.39	163.37	37.28
Short-Term Investments	187.59	144.57	-	-	-
Cash & Short-Term Investments	300.27	218.86	150.39	163.37	37.28
Cash Growth	6.16%	45.53%	-7.95%	338.23%	-
Other Receivables	0.51	0.5	0.76	0.5	0.25
Receivables	0.51	0.5	0.76	0.5	0.25
Prepaid Expenses	0.55	0.41	0.37	0.33	0.03
Other Current Assets	19.9	7.21	8.45	18.42	5.39
Total Current Assets	321.22	226.98	159.97	182.62	42.95
Property, Plant & Equipment	0.05	0.15	0.29	0.14	-
Long-Term Investments	5.11	47.68	-	-	-
Long-Term Deferred Charges	-	-	2.73	-	-
Other Long-Term Assets	0.18	0.13	0.11	0.07	0.09
Total Assets	326.56	274.94	163.1	182.83	43.04
Accounts Payable	5.93	3.78	4.53	3.09	0.29
Accrued Expenses	15.57	13.33	6.95	5.14	1.53
Current Portion of Leases	0.06	0.16	0.14	0.13	-
Total Current Liabilities	21.56	17.27	11.62	8.36	1.82
Long-Term Leases	-	0.01	0.18	0.01	-
Total Liabilities	21.56	17.29	11.8	8.37	1.82
Common Stock	0	0	-	-	-
Additional Paid-In Capital	673.88	496.2	4.65	3.4	2.96
Retained Earnings	-369.1	-238.33	-157.85	-88.51	-51.61
Comprehensive Income & Other	0.21	-0.21	-	-	-0
Total Common Equity	305	257.65	-153.19	-85.11	-48.64
Shareholders' Equity	305	257.65	151.3	174.46	41.22
Total Liabilities & Equity	326.56	274.94	163.1	182.83	43.04
Total Debt	0.06	0.18	0.32	0.14	-
Net Cash (Debt)	300.21	218.69	150.07	163.23	37.28
Net Cash Growth	6.22%	45.72%	-8.06%	337.86%	-
Net Cash Per Share	8.30	6.95	70.10	127.82	52.42
Filing Date Shares Outstanding	41.28	34.02	33.49	31.96	0.71
Total Common Shares Outstanding	40.85	33.71	2.75	2.6	0.71
Working Capital	299.66	209.71	148.34	174.26	41.13
Book Value Per Share	7.47	7.64	-55.80	-32.76	-68.40
Tangible Book Value	305	257.65	-153.19	-85.11	-48.64
Tangible Book Value Per Share	7.47	7.64	-55.80	-32.76	-68.40

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q